GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global RVO industry . The report identifies the major industry developments shaping and driving the global RVO industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global RVO segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

GlobalData valued the Retinal Vein Occlusion (RVO) therapeutics industry in 2010 at USD 496m, indicating a growth rate of 29.25% between 2005 and 2010. Until the industry entry of Lucentis (ranibizumab) in 2006, the RVO therapeutics industry was growing at a lower rate. After the entry of Lucentis, the industry registered a growth rate of 40.13% between 2006 and 2007. Up until now, Lucentis and Ozurdex have been the only approved drugs for the treatment of RVO. The late-stage clinical development pipeline consists of 50% first-in-class and 50% me-too drugs that are effective and safe for RVO patients. Once these drugs enter the industry, the industry will grow further at a significant rate. Therefore, GlobalData estimates that the RVO therapeutics industry in 2017 will be USD 1.4 billion, indicating a Compound Annual Growth Rate (CAGR) of 16.08% between 2010 and 2017

Scope of the Research

The report provides data on the key drivers and challenges of the retinal vein occlusion therapeutics industry . Its scope includes -
- Annualized seven key industry s (US, France, Germany, Italy, Spain, UK and Japan) retinal vein occlusion therapeutics industry revenues data 2005-2010, projection for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key industry s. Pipeline candidates fall under major therapeutic classes such as VEGF inhibitors, HMG CoA reductase inhibitors, Glucocorticoid receptor agonists, and kallikrein inhibitors.
- Analysis of the current and future competition in the seven key countries retinal vein occlusion industry . Key industry players covered are Allergan, Inc., Alimera Sciences, Icon Biosciences, and Regeneron Pharmaceuticals.
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the retinal vein occlusion therapeutics industry .
- Analysis of key recent licensing and partnership agreements in retinal vein occlusion industry

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global retinal vein occlusion industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global retinal vein occlusion industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global retinal vein occlusion industry landscape? – Identify, understand and decide.

Table Of Contents

1 Table of contents

I Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 5

II Retinal Vein Occlusion Therapeutics: Introduction 6
II. 1 Overview 6
II. 2 Epidemiology 7
II. 3 Etiology and Pathophysiology 8
II. 4 Signs and Symptoms 8
II. 5 Diagnosis 9
II. 6 Treatment 9
II. 7 GlobalData Pipeline Report Guidance 12

III Retinal Vein Occlusion Therapeutics: March ket Characterization 13
III. 1 Retinal Vein Occlusion Therapeutics March ket Size (2005-2010) 13
III. 2 Retinal Vein Occlusion Therapeutics March ket Forecasted data (2010-2017) 14
III. 3 Retinal Vein Occlusion Therapeutics March ket Size (2005-2010) - The US 15
III. 4 Retinal Vein Occlusion Therapeutics March ket Forecasted data (2010-2017) - The US 16
III. 5 Retinal Vein Occlusion Therapeutics March ket Size (2005-2010) - France 17
III. 6 Retinal Vein Occlusion Therapeutics March ket Forecasted data (2010-2017) - France 18
III. 7 Retinal Vein Occlusion Therapeutics March ket Size (2005-2010) - Germany 19
III. 8 Retinal Vein Occlusion Therapeutics March ket Forecasted data (2010-2017) - Germany 20
III. 9 Retinal Vein Occlusion Therapeutics March ket Size (2005-2010) - Italy 21
III. 10 Retinal Vein Occlusion Therapeutics March ket Forecasted data (2010-2017) - Italy 22
III. 11 Retinal Vein Occlusion Therapeutics March ket Size (2005-2010) - Spain 23
III. 12 Retinal Vein Occlusion Therapeutics March ket Forecasted data (2010-2017) - Spain 24
III. 13 Retinal Vein Occlusion Therapeutics March ket Size (2005-2010) - The UK 25
III. 14 Retinal Vein Occlusion Therapeutics March ket Forecasted data (2010-2017) - The UK 26
III. 15 Retinal Vein Occlusion Therapeutics March ket Size (2005-2010) - Japan 27
III. 16 Retinal vein Occlusion Therapeutics March ket Forecasted data (2010-2017) - Japan 28
III. 17 Drivers and Barriers for Retinal Vein Occlusion Therapeutics March ket 29
III. 17.1 Drivers for the Retinal Vein Occlusion Therapeutics March ket 29
III. 17.2 Barriers for Retinal Vein Occlusion Therapeutics March ket 29
III. 18 Opportunity and Unmet Need Analysis 30
III. 19 Key Takeaway 31

IV Retinal Vein Occlusion Therapeutics: Competitive Assessment 32
IV. 1 Overview 32
IV. 2 Strategic Competitor Assessment 32
IV. 3 Product Profile for the Major March keted Products in the Retinal Vein Occlusion Therapeutics March ket 33
IV. 3.1 Lucentis (ranibizumab) 33
IV. 3.2 Ozurdex (dexamethasone implpant) 34
IV. 4 Key Takeaway 35

V Retinal Vein Occlusion Therapeutics: Pipeline Assessment 37
V. 1 Overview 37
V. 2 Strategic Pipeline Assessment 37
V. 3 Retinal Vein Occlusion Therapeutic Pipeline - Pipeline by Clinical Phases of Development 37
V. 3.1 Retinal Vein Occlusion Therapeutics - Regulatory Filing and Phase III Pipeline 37
V. 3.2 Retinal Vein Occlusion Therapeutics - Phase II Pipeline 38
V. 3.3 Retinal Vein Occlusion Therapeutics - Phase I Pipeline 38
V. 3.4 Technology Trends Analytic Framework 39
V. 4 Retinal Vein Occlusion Therapeutics March ket - Clinical Pipeline by Mechanism of Action 41
V. 4.1 Retinal Vein Occlusion - Promising Drugs Under Clinical Development 42
V. 5 Molecule Profile for Promising Drugs Under Clinical Development 42
V. 5.1 VEGF Trap Eye 42
V. 5.2 IBI-20089 43
V. 6 Key Takeaway 44

VI Retinal Vein Occlusion Therapeutics: Clinical Trials Mapping 45
VI. 1 Clinical Trials by Region/Country (US, EU5 and Japan) 45
VI. 2 Clinical Trials by Phase 46
VI. 3 Clinical Trials by Trial Status 47
VI. 4 Key Sponsors 48
VI. 5 Top Firms Participating in Clinical Trials 50

VII Strategic Assessment 51
VII. 1 Key Events Impacting the Future March ket 51
VII. 2 Retinal Vein Occlusion Therapeutics: Implications for Future March ket Competition 52

VIII Retinal Vein Occlusion Therapeutics: Future Players 53
VIII. 1 Introduction 53
VIII. 2 Firms Profiles 53
VIII. 2.1 Allergan, Inc. 53
VIII. 2.2 Alimera Sciences 56
VIII. 2.3 Bayer AG 57
VIII. 2.4 Fovea Pharmaceuticals SA 61
VIII. 2.5 Icon Biosciences 62
VIII. 2.6 Regeneron Pharmaceuticals 62
VIII. 2.7 Suzuken Co.Ltd. 64

IX Licensing and Partnership Deals 66

X Retinal Vein Occlusion Therapeutics: Appendix 67
X. 1 March ket Definitions 67
X. 2 Abbreviations 67
X. 3 Methodology 68
X. 3.1 Coverage 68
X. 3.2 Secondary Research 68
X. 3.3 Forecasted data ing 69
X. 3.4 Primary Research 71
X. 3.5 Expert Panel Validation 72
X. 4 Contact Us 72
X. 5 Disclaimer 72
X. 6 Bibliography 72

1.1 List of Data tables

Data table 1: Retinal Vein Occlusion Therapeutics March ket, Global, Sales (USD Million), 2005-2010 13
Data table 2: Retinal Vein Occlusion Therapeutics March ket, Global, Forecasted data s (USD Million), 2010-2017 14
Data table 3: Retinal Vein Occlusion Therapeutics March ket, The US, Sales (USD Million), 2005-2010 15
Data table 4: Retinal Vein Occlusion Therapeutics March ket, The US, Forecasted data s (USD Million), 2010-2017 16
Data table 5: Retinal Vein Occlusion Therapeutics March ket, France, Sales (USD Million), 2005-2010 17
Data table 6: Retinal Vein Occlusion Therapeutics March ket, France, Forecasted data s (USD Million), 2010-2017 18
Data table 7: Retinal Vein Occlusion Therapeutics March ket, Germany, Sales (USD Million), 2005-2010 19
Data table 8: Retinal Vein Occlusion Therapeutics March ket, Germany, Forecasted data s (USD Million), 2010-2017 20
Data table 9: Retinal Vein Occlusion Therapeutics March ket, Italy, Sales (USD Million), 2005-2010 21
Data table 10: Retinal Vein Occlusion Therapeutics March ket, Italy, Forecasted data s (USD Million), 2010-2017 22
Data table 11: Retinal Vein Occlusion Therapeutics March ket, Spain, Sales (USD Million), 2005-2010 23
Data table 12: Retinal Vein Occlusion Therapeutics March ket, Spain, Forecasted data s (USD Million), 2010-2017 24
Data table 13: Retinal Vein Occlusion Therapeutics March ket, The UK, Sales (USD Million), 2005-2010 25
Data table 14: Retinal Vein Occlusion Therapeutics March ket, The UK, Forecasted data s (USD Million), 2010-2017 26
Data table 15: Retinal Vein Occlusion Therapeutics March ket, Japan, Sales (USD Million), 2005-2010 27
Data table 16: Retinal Vein Occlusion Therapeutics March ket, Japan, Forecasted data s (USD Million), 2010-2017 28
Data table 17: Efficacy and Safety Profile of Lucentis 34
Data table 18: Retinal Vein Occlusion Therapeutics, Historical data al Sales of Lucentis (USD Million) 34
Data table 19: Number (%) of Patients With ? 15 Letters Improvement from Baseline in BCVA 35
Data table 20: Adverse Reactions Reported by >2% of Patients in the First Six Months 35
Data table 21: Retinal Vein Occlusion Therapeutics, March keted Products Comparison, 2010 36
Data table 22: Retinal Vein Occlusion Therapeutics, Phase III Pipeline, 2011 37
Data table 23: Retinal Vein Occlusion Therapeutics, Phase II Pipeline, 2011 38
Data table 24: Retinal Vein Occlusion Therapeutics, Phase I Pipeline, 2011 38
Data table 25: Retinal Vein Occlusion Therapeutics, Most Promising Drugs Under Clinical Development, 2011 42
Data table 26: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2011 45
Data table 27: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase, 2011 46
Data table 28: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status, 2011 47
Data table 29: Retinal Vein Occlusion Therapeutics, Overall Sponsors, 2011 48
Data table 30: Retinal Vein Occlusion Therapeutics, Key Sponsors, 2011 49
Data table 31: Retinal Vein Occlusion Therapeutics, Top Firms Participating in Clinical Trials, 2011 50
Data table 32: Retinal Vein Occlusion Therapeutics, Allergan, Retinal Vein Occlusion Pipeline, 2011 55
Data table 33: Allergan, Inc. Deals, from 2009 to 2011 55
Data table 34: Retinal Vein Occlusion Therapeutics, Alimera Sciences, Ophthalmology Pipeline, 2011 56
Data table 35: Retinal Vein Occlusion Therapeutics, Alimera Sciences, Retinal Vein Occlusion Pipeline, 2011 56
Data table 36: Alimera Sciences Deals, from 2009 to 2011 57
Data table 37: Retinal Vein Occlusion Therapeutics, Bayer AG, Ophthalmology Pipeline, 2011 59
Data table 38 Retinal Vein Occlusion Therapeutics, Bayer AG, Retinal Vein Occlusion Pipeline, 2011 59
Data table 39: Bayer AG Deals, from 2009 to 2011 60
Data table 40: Fovea Pharmaceuticals Deals, from 2009 to 2011 61
Data table 41: Retinal Vein Occlusion Therapeutics, Regeneron Pharmaceuticals, Ophthalmology Pipeline, 2011 63
Data table 42: Retinal Vein Occlusion Therapeutics, Regeneron Pharmaceuticals, Retinal Vein Occlusion Pipeline, 2011 63
Data table 43: Regeneron Pharmaceuticals Deals, from 2009 to 2011 64
Data table 44: Retinal Vein Occlusion Therapeutics, Global, Deals, from 2008 to 2011 66

1.2 List of Charts

Chart 1: Eye Diagram Depicting Normal and Effected Blood Vessels 6
Chart 2: Recent Onset Central Retinal Vein Occlusion, Showing Extensive Hemorrhages in the Posterior Pole and Creating the “Blood and Thunder Appearance” 7
Chart 3: Peripheral Fundus View, Showing Hemorrhages Extending All Over the Fundus 7
Chart 4: Fluorescein Angiograph Showing Hypofluorescence Due to Hemorrhages in Retina 9
Chart 5: Treatment Algorithm for RVO 9
Chart 6: Preferred Treatment for Macular Edema Following BRVO 11
Chart 7: Preferred Treatment for Cystoid Macular Edema Following CRVO 11
Chart 8: Retinal Vein Occlusion Therapeutics March ket, Global, Sales (USD Million), 2005-2010 13
Chart 9: Retinal Vein Occlusion Therapeutics March ket, Global, Forecasted data (USD Million), 2010-2017 14
Chart 10: Retinal Vein Occlusion Therapeutics March ket, The US, Sales (USD Million), from 2005 to 2010 15
Chart 11: Retinal Vein Occlusion Therapeutics March ket, The US, Forecasted data (USD Million), 2010-2017 16
Chart 12: Retinal Vein Occlusion Therapeutics March ket, France, Sales (USD Million), 2005-2010 17
Chart 13: Retinal Vein Occlusion Therapeutics March ket, France, Forecasted data (USD Million), 2010-2017 18
Chart 14: Retinal Vein Occlusion Therapeutics March ket, Germany, Sales (USD Million), 2005-2010 19
Chart 15: Retinal Vein Occlusion Therapeutics March ket, Germany, Forecasted data (USD Million), 2010-2017 20
Chart 16: Retinal Vein Occlusion Therapeutics March ket, Italy, Sales (USD Million), 2005-2010 21
Chart 17: Retinal Vein Occlusion Therapeutics March ket, Italy, Forecasted data (USD Million), 2010-2017 22
Chart 18: Retinal Vein Occlusion Therapeutics March ket, Spain, Sales (USD Million), 2005-2010 23
Chart 19: Retinal Vein Occlusion Therapeutics March ket, Spain, Forecasted data (USD Million), 2010-2017 24
Chart 20: Retinal Vein Occlusion Therapeutics March ket, The UK, Sales (USD Million), 2005-2010 25
Chart 21: Retinal Vein Occlusion Therapeutics March ket, The UK, Forecasted data (USD Million), 2010-2017 26
Chart 22: Retinal Vein Occlusion Therapeutics March ket, Japan, Sales (USD Million), 2005-2010 27
Chart 23: Retinal Vein Occlusion Therapeutics March ket, Japan, Forecasted data (USD Million), 2010-2017 28
Chart 24: Opportunity and Unmet Need in the Retinal Vein Occlusion Therapeutics March ket, 2010 30
Chart 25: Retinal Vein Occlusion Therapeutics, Strategic Competitor Assessment, 2010 32
Chart 26: Retinal Vein Occlusion Therapeutics, Pipeline by Phase of Development, 2011 37
Chart 27: Retinal Vein Occlusion Therapeutics, Technology Trends Analytics Framework, 2011 39
Chart 28: Retinal Vein Occlusion Therapeutics, Technology Trends Analytics Framework, Description, 2011 40
Chart 29: Retinal Vein Occlusion Therapeutics, Pipeline by Mechanism of Action (%), 2011 41
Chart 30: IBI-20089 Interim Optical Coherence Tomography (OCT) results 44
Chart 31: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2011 45
Chart 32: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase (%), 2011 46
Chart 33: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status (%), 2011 47
Chart 34: Retinal Vein Occlusion Therapeutics, Overall Sponsors (%), 2011 48
Chart 35: Retinal Vein Occlusion Therapeutics, Key Sponsors (%), 2011 49
Chart 36: Retinal Vein Occlusion Therapeutics, Top Firms Participating in Clinical Trials, 2011 50
Chart 37: Retinal Vein Occlusion Therapeutics March ket, Drivers and Restraints, 2011 51
Chart 38: Implications for Future March ket Competition in the Retinal Vein Occlusion Therapeutics March ket, 2011 52
Chart 39: Retinal Vein Occlusion Therapeutics March ket, Pipeline by Firms, 2011 53
Chart 40: GlobalData March ket Forecasted data ing Model 71

Companies MentionedAllergan, Inc.
Alimera Sciences
Bayer AG
Fovea Pharmaceuticals SA
Icon Biosciences
Regeneron Pharmaceuticals
Suzuken Co.Ltd.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

Inflammation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline. This report provides ...

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • April 2014
  • by Global Markets Direct

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Corcept Therapeutics Incorporated - Product Pipeline Review - 2014', provides an overview of the Corcept ...

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.